ATS 2022
TRAVERSE Trial of Dupilumab for Severe Oral Corticosteroid-Dependent Asthma
TRAVERSE trial findings on the efficacy, safety, and OCS-sparring effect of dupilumab for severe OCS-dependent asthma were presented at ATS 2022.
Your search for oral corticosteroids returned 9 results
ATS Virtual Program 2020
Low-Severity COPD: Risk for Exacerbation, Hospitalization, and Death
What is the risk of future COPD exacerbations, hospitalizations, and death among patients with COPD who had 1 or 0 exacerbation in the previous 12 months?
AAAAI 2022
Azithromycin and Recurrent Wheeze in Children After Severe RSV Bronchiolitis
Research presented at AAAAI assessed the effectiveness of oral azithromycin in reducing recurrent wheeze in young children.
AAAAI 2022
Atopy Status of Patients With Asthma and Exacerbation Rates Post COVID-19
Does the allergic status of patients with asthma affect asthma exacerbation rates and outcomes following COVID-19?
AAAAI 2022
Escalation to Biologics in Asthma: The Role of Suboptimal Treatment Adherence
To what extent are patients with uncontrolled asthma switched to biologics due to poor treatment adherence vs lack of maintenance therapy efficacy?
ACAAI 2021
Can a Patient’s Asthma Impairment and Risk Questionnaire Score Predict HRQoL?
Asthma control as measured by AIRQ may predict 12-month HRQoL, according to research reported at the 2021 ACAAI Annual Scientific Meeting.
CHEST 2021, News
A New Basis for Predicting Future COPD Exacerbations During the Pandemic
Research presented at CHEST 2021 assessed an alternative approach to predicting COPD exacerbations during the COVID-19 pandemic.
CHEST 2021, News
Dupilumab Improves Severe Asthma Outcomes, Regardless of Baseline OCS Dose
A post-hoc analysis of the VENTURE trial evaluated whether baseline oral corticosteroid dosage affected the efficacy of dupilumab in improving severe asthma outcomes.
CHEST 2021, News
Tezepelumab Improves Lung Function in Severe, Uncontrolled Asthma
NAVIGATOR trial results presented at CHEST 2021 show the effect of tezepelumab on peak expiratory flow rates in severe asthma.
